The Manufacturers Life Insurance Company Sells 37,264 Shares of Danaher Corporation $DHR

Key Points

• The Manufacturers Life Insurance Company reduced its stake in Danaher Corporation by 1.9%, selling 37,264 shares, and now holds 1,907,845 shares valued at approximately $391 million.
• Danaher recently reported $1.80 EPS for the last quarter, exceeding analysts' expectations of $1.64, with a revenue of $5.94 billion.
• Analysts have set a consensus target price of $247.61 for Danaher, indicating strong optimism with seventeen ratings of "Buy" and three "Hold".

The Manufacturers Life Insurance Company decreased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,907,845 shares of the conglomerate's stock after selling 37,264 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.27% of Danaher worth $391,109,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after acquiring an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after acquiring an additional 194,466 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Danaher by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after buying an additional 579,046 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of recent analyst reports. Robert W. Baird lifted their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Guggenheim reaffirmed a "buy" rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Barclays reissued an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Wells Fargo & Company lowered their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 11.20% of the stock is owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock traded down $2.02 during trading hours on Tuesday, hitting $203.80. The stock had a trading volume of 2,355,407 shares, compared to its average volume of 4,161,081. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock's 50 day moving average is $201.84 and its 200 day moving average is $199.46. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The firm has a market capitalization of $145.93 billion, a PE ratio of 43.36, a PEG ratio of 2.87 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the company earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.